NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology

NeuroOne will receive approximately $200,000 initially, with additional funds expected during the following two years.

Rhea-AI Summary

NeuroOne (NMTC) entered a research and development subaward agreement with Dartmouth to advance neurotransmitter sensing technology toward potential human use. NeuroOne will receive approximately $200,000 through April 30, 2027, with additional funds expected during the following two years.

The Dartmouth-led team received an NIH grant of approximately $1 million for the first year through the NIH BRAIN Initiative. The collaboration includes the VA Medical Center and Beth Israel Deaconess Medical Center. It seeks to combine neurochemical sensing with NeuroOne’s sEEG electrodes, which record electrical activity in the brain, to monitor electrical and neurochemical signals in real time.

Positive

• Minor point. Forward-looking: it has not happened yet and may not happen.Dartmouth research subaward provides NeuroOne approximately $200,000 through April 30, 2027.
• Minor point. Forward-looking: it has not happened yet and may not happen.NeuroOne expects additional funds during the following two years.

Negative

• None.

Argus 15 min delay 14 alerts

-5.46% vs previous close $1.02 last price 2.5x rel. volume Open Argus

Details

Market move: NMTC -5.46% vs previous close. NIH research partnership

+9.3% Peak Tracked

-19.5% Trough Tracked

$0.95 – $1.29 Day Range

$9.30M Market Cap

On Oct 8, the day this news came out, the latest delayed price for NMTC is 5.46% below the previous close. Argus tracked a peak move of +9.3% during the session. Argus tracked a trough of -19.5% from its starting point during tracking. Our momentum scanner has recorded 14 alerts for this stock so far that day. The latest delayed price is $1.02. Relative volume is elevated at 2.5x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

First-year NIH grant: approximately $1 million NeuroOne subaward: approximately $200,000

First-year NIH grant

approximately $1 million

First year; grant awarded to the Dartmouth-led research team

NeuroOne subaward

approximately $200,000

Through April 30, 2027

Key Terms

sEEG, subaward agreement

2 terms

sEEG medical

"using NeuroOne’s sEEG electrodes"

Stereoelectroencephalography (SEEG) is an invasive brain-monitoring technique that records electrical activity from deep regions of the brain using thin, stereotactically placed depth electrodes. It is used to map where seizures start and how they spread by sampling multiple deep and cortical sites simultaneously; unlike surface EEG or subdural grid electrodes, SEEG accesses buried brain structures through small burr holes and does not require a large craniotomy. SEEG is a diagnostic procedure (not a treatment) and carries risks associated with intracranial electrode placement such as bleeding and infection.

subaward agreement financial

"entered into a research and development subaward agreement with Dartmouth"

A subaward agreement is a legal contract in which a primary recipient of a grant, loan, or contract (the prime awardee) authorizes another organization (the subrecipient) to perform a defined portion of the work and receive part of the award funds. It sets out the scope of work, budget, reporting and audit requirements, and any award terms that must be passed down, and it creates compliance responsibilities for the subrecipient distinct from a simple vendor purchase. A subaward is used to delegate programmatic work and related compliance obligations, not merely to buy goods or routine services for the prime recipient's own use.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New NIH Award will Initially Provide NeuroOne Approximately $200,000 through April 2027

EDEN PRAIRIE, Minn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced it has entered into a research and development subaward agreement with Dartmouth to support the advancement of next-generation neurotransmitter sensing technology.

Researchers at Dartmouth College, led by Associate Professor of Engineering Hui Fang, have received a National Institutes of Health (NIH) grant of approximately $1 million for the first year, with additional funding expected during the following two years. The grant is titled “Translating Novel Carbon Coating Towards Integrated Sub-Second Neurotransmitter Sensors in Humans,” which is funded by the National Institute of Neurological Disorders and Stroke (NINDS) through the NIH BRAIN Initiative. NeuroOne will receive approximately $200,000 through April 30, 2027, with additional funds expected during the following two years.

The collaborative effort brings together expertise from Dartmouth, the VA Medical Center, Beth Israel Deaconess Medical Center, and NeuroOne to translate recent advances in neurochemical sensing toward potential use in humans.

The collaboration seeks to combine advanced neurochemical sensing capabilities with clinically relevant neural interface technologies to provide physicians and researchers with new tools for monitoring brain activity and neurochemical signaling in real time using NeuroOne’s sEEG electrodes. The ability to simultaneously measure electrical and neurochemical activity help advance understanding, diagnosis, and treatment of neurological and psychiatric disorders.

“We are excited to collaborate with Dartmouth on this NIH-supported initiative,” said Dave Rosa, CEO of NeuroOne. “This grant is another compelling example of the versatility and potential of NeuroOne’s thin-film electrode technology platform. While our technology has already demonstrated value in recording, stimulation, and therapeutic applications, we believe its flexible design and high-performance characteristics create opportunities well beyond those uses.”

About NeuroOne

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo^® Cortical Electrodes, Evo^® sEEG Electrodes, OneRF^® Ablation System (for brain), and OneRF^® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue," "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential receipt of funds from the NIH-grant. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, our partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages, risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

Company Contact:
800-631-4030
ir@nmtc1.com

Investor Relations:
MZ Group - MZ North America
949-491-8235
NMTC@mzgroup.us

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much funding will NeuroOne receive under the Dartmouth research subaward?

NeuroOne will receive approximately $200,000 through April 30, 2027. Additional funds are expected during the following two years.

What is NeuroOne developing in the Dartmouth-led NIH research collaboration?

The collaboration seeks to combine neurochemical sensing with NeuroOne’s sEEG electrodes for real-time monitoring of electrical and neurochemical brain activity. The research aims to translate advances in neurotransmitter sensing toward potential use in humans.